16313-65-8|2-Amino-5-nitrobenzamide| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 16313-65-8 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 16313-65-8 ]

CAS No. :	16313-65-8
Formula :	C₇H₇N₃O₃
M.W :	181.15
SMILES Code :	NC(=O)C1=C(N)C=CC(=C1)[N+]([O-])=O
MDL No. :	MFCD00090235
InChI Key :	SOBQOVZAFJDEJI-UHFFFAOYSA-N
Pubchem ID :	97665

Safety of [ 16313-65-8 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H317-H319
Precautionary Statements:	P280-P305+P351+P338

Computational Chemistry of [ 16313-65-8 ] Show Less

Physicochemical Properties

Num. heavy atoms	13
Num. arom. heavy atoms	6
Fraction Csp3	0.0
Num. rotatable bonds	2
Num. H-bond acceptors	3.0
Num. H-bond donors	2.0
Molar Refractivity	47.76
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	114.93 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.48
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	1.26
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	0.28
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	-0.44
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-1.86
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	-0.05

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-1.97
Solubility	1.96 mg/ml ; 0.0108 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-3.27
Solubility	0.0968 mg/ml ; 0.000534 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-1.01
Solubility	17.7 mg/ml ; 0.0979 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	No
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.51 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	3.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.73

Application In Synthesis of [ 16313-65-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 16313-65-8 ]

[ 16313-65-8 ] Synthesis Path-Downstream 1~35

1
[ 16313-65-8 ]
[ 91532-29-5 ]

Yield	Reaction Conditions	Operation in experiment
		General procedure: A solution of anthranilamide (I, 30 mmol) in DMF (15 mL) was added dropwise to a well-stirred solution of sodium nitrite (4.14 g, 60 mmol) in 0.5 M HCl (240 mL) at 0 C over a period of 40 min. After the stirring was continued at 0-5 C for 1 h, 30% aqueous ammonia was added slowly to adjust the pH to 10.0, and then reacidified to pH 2.0. After vigorously stirring for 30 min, the mixture was filtered with suction, and the filter cake was washed with water (200 mL) and dried to afford 1,2,3-benzotriazin-4-one II in yields of above 80%.
		General procedure: A solution of anthranilamide (30 mmol) in 1 N HCl (120 mL) was stirred at 0 C for 20 min. Then, sodium nitrite (60 mmol) dissolved in deionized water (100 mL) was added dropwise to the above solution for 40 min. After another 2 h of stirring at 0 C, 30% NaOH solution was added slowly to adjust the pH to 8.0. The reaction mixture was allowed to stir vigorously for 15 min. The precipitated product was filtered off with suction, washed with deionized water (200 mL), and dried to afford compound 4 in yield of 82%.
		General procedure: A solution of anthranilamide (30 mmol) in 1N HCl (120 mL) was stirred at 0 C for 20 min. Then, sodium nitrite (60 mmol) dissolved in deionized water (100 mL) was added dropwise to the above solution for 40 min. After another 2 h of stirringat 0 C, 30% NaOH solution was added slowly to adjustp H value to 8.0. The reaction mixture was allowed to stir vigorously for 15 min. The precipitated product was filtered, washed with deionized water (200 mL), and dried to afford compounds 10 in yields of 40-92%.

References: [1]Journal fur praktische Chemie (Leipzig 1954),1896,vol. <2> 53,p. 222.
[2]Journal of Agricultural and Food Chemistry,2015,vol. 63,p. 6883 - 6889.
[3]Chinese Chemical Letters,2017,vol. 28,p. 1044 - 1048.
[4]Chinese Chemical Letters,2019,vol. 30,p. 1207 - 1213.
[5]Phosphorus, Sulfur and Silicon and the Related Elements,2020,vol. 195,p. 194 - 200.

2
[ 41052-26-0 ]
[ 16313-65-8 ]

References: [1]Chemische Berichte,1891,vol. 24,p. 3814.

3
[ 87-48-9 ]
[ 16313-65-8 ]

References: [1]Journal of the Chemical Society,1948,p. 1713.

4
[ 16313-65-8 ]
[ 4755-77-5 ]
[ 54166-78-8 ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 47 2'-Carbamoyl-4'-nitrooxanilic acid ethyl ester. 59 <strong>[16313-65-8]<strong>[16313-65-8]2-Amino-5-nitrobenzamid</strong>e</strong> (5.43 g. 0.03 mole) is condensed with 3.7 ml (0.033 mole) of ethyl oxalyl chloride in a manner similar to example 3, giving 6.54 g of the title compound, m.p. 206-209 C., after crystallization from ethanol. Elemental Analysis for C11 H11 N3 O6: Calc'd: C, 46.98; H, 3.94; N, 14.94. Found: C, 46.68; H, 3.96; N, 15.12.
		EXAMPLE 30 2'-Carbamoyl-4'-nitrooxanilic acid ethyl ester. 59 <strong>[16313-65-8]<strong>[16313-65-8]2-Amino-5-nitrobenzamid</strong>e</strong> (5.43 g., 0.03 mole) is condensed with 3.7 ml. (0.033 mole) of ethyl oxalyl chloride in a manner similar to example 12, giving 6.54 g. of the title compound, m.p. 206-209 C., after crystallization from ethanol. Elemental Analysis for C11 H11 N3 O6: Calc'd: C, 46.98; H, 3.94; N, 14.94: Found: C, 46,68; H, 3.96; N, 15.12.
		EXAMPLE 30 2'-Carbamoyl-4'-nitrooxanilic acid ethyl ester. 59 <strong>[16313-65-8]<strong>[16313-65-8]2-Amino-5-nitrobenzamid</strong>e</strong> (5.43 g., 0.03 mole) is condensed with 3.7 ml. (0.033 mole) of ethyl oxalyl chloride in a manner similar to example 12, giving 6.54 g. of the title compound, m.p. 206-209 C., after crystallization from ethanol. Elemental Analysis for C11 H11 N3 O6: Calc'd: C, 46.98; H, 3.94; N, 14.94. Found: C, 46,68; H, 3.96; N, 15.12.

		EXAMPLE 30 2'-Carbamyl-4'-nitrooxanilic acid ethyl ester. 59 <strong>[16313-65-8]<strong>[16313-65-8]2-Amino-5-nitrobenzamid</strong>e</strong> (5.43 g., 0.03 mole) is condensed with 3.7 ml. (0.033 mole) of ethyl oxalyl chloride in a manner similar to example 12, giving 6.54 g. of the title compound, m.p. 206-209 C., after crystallization from ethanol. Elemental Analysis for C11 H11 N3 O6: Calc'd: C, 46.98; H, 3.94; N, 14.94. Found: C, 46,68; H, 3.96; N, 15.12.
		EXAMPLE 47 2'-Carbamoyl-4'-nitrooxanilic acid ethyl ester. 59 <strong>[16313-65-8]<strong>[16313-65-8]2-Amino-5-nitrobenzamid</strong>e</strong> (5.43 g, 0.03 mole) is condensed with 3.7 ml (0.033 mole) of ethyl oxalyl chloride in a manner similar to example 3, giving 6.54 g of the title compound, m.p. 206-209 C., after crystallization from ethanol. Elemental Analysis for C11 H11 N3 O6: Calc'd: C, 46.98; H, 3.94; N, 14.94. Found: C, 46.68; H, 3.96; N, 15.12.
	With triethylamine; In tetrahydrofuran; at 0℃; for 1h;	Step 2 To a solution of <strong>[16313-65-8]2-amino-5-nitrobenzamide</strong> (18.1 g) and triethylamine (15 mL) in THF (100 mL) was added dropwise a solution of ethyl chloroglyoxylate (14.4 g) in THF (20 mL) under ice-cooling, and the mixture was stirred at 0C for 1hr. 1N Hydrochloric acid was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water, saturated aqueous sodium hydrogencarbonate and saturated brine, dried, and concentrated. The obtained crude crystals were washed with diisopropyl ether to give ethyl [2-(aminocarbonyl)-4-nitrophenyl]amino}(oxo)acetate (8.1 g). 1H-NMR (300MHz, DMSO-d6) delta: 1.37 (3H, t, J = 7.1 Hz), 3.33 (3H, s), 4.41 (2H, q, J = 7.1 Hz), 8.03 (1H, d, J = 8.8 Hz), 8.59 (1H, dd, J = 8.8, 2.7 Hz), 8.83 (1H, d, J = 2.2 Hz).
8.1 g	With triethylamine; In tetrahydrofuran; at 0℃; for 1h;	Step 2 To a solution of <strong>[16313-65-8]2-amino-5-nitrobenzamide</strong> (18.10 g) and triethylamine (15 ml) in THF (100 mL) was added dropwise a solution of ethyl chloroglyoxylate (14.36 g) in THF (20 ml) under ice-cooling, and the mixture was stirred at 0 C. for 1 hr. 1N Hydrochloric acid was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with water, saturated aqueous sodium hydrogen carbonate and saturated brine, dried and concentrated. The obtained crude crystals were washed with diisopropy ether to give ethyl [2-(aminocarbonyl)-4-nitrophenyl]amino}(oxo)acetate (8.1 g). 1H NMR (300 MHz, DMSO-d6) delta: 1.4 (t, J=7.1 Hz, 2H) 3.3 (s, 3H) 4.4 (q, J=7.1 Hz, 2H) 8.0 (d, J=8.8 Hz, 1H) 8.6 (dd, J=8.8, 2.7 Hz, 1H) 8.8 (d, J=2.2 Hz, 1H)
		EXAMPLE 47 2'-Carbamoyl-4'-nitrooxanilic acid ethyl ester. 59 <strong>[16313-65-8]<strong>[16313-65-8]2-Amino-5-nitrobenzamid</strong>e</strong> (5.43 g, 0.03 mole) is condensed with 3.7 ml (0.033 mole) of ethyl oxalyl chloride in a manner similar to example 3, giving 6.54 g of the title compound, m.p. 206-209C., after crystallization from ethanol. Elemental Analysis for C11 H11 N3 O6: Calc'd: C, 46.98; H, 3.94; N, 14.94. Found: 46.68; H, 3.96; N, 15.12.

References: [1]Journal of Medicinal Chemistry,1975,vol. 18,p. 926 - 933.
[2]Patent: US4054661,1977,A .
[3]Patent: US4191840,1980,A .
[4]Patent: US4069343,1978,A .
[5]Patent: US4154961,1979,A .
[6]Patent: US4160100,1979,A .
[7]Patent: EP1953148,2008,A1 .Location in patent: Page/Page column 131.
[8]Patent: US2015/329556,2015,A1 .Location in patent: Paragraph 1772-1773.
[9]Patent: US3966965,1976,A .

5
[ 617-35-6 ]
[ 16313-65-8 ]
2-Methyl-6-nitro-4-oxo-1,2,3,4-tetrahydrochinazolin-2-carbonsaeureethylester [ No CAS ]

References: [1]Archiv der Pharmazie,1994,vol. 327,p. 571 - 579.

6
[ 17420-30-3 ]
[ 16313-65-8 ]

Yield	Reaction Conditions	Operation in experiment
	With sulfuric acid; at 130℃; for 0.666667h;	Step 1 A mixture of 2-amino-5-nitrobenzonitrile (25.4 g) and sulfuric acid (70 mL) was stirred at 130C for 40 min. The reaction mixture was added slowly to ice water, and the precipitate was collected by filtration, washed with water, ethanol and diethyl ether to give 2-amino-5-nitrobenzamide (24.6 g).
24.63 g	With sulfuric acid; at 130℃; for 0.666667h;	Step 1 A mixture of 2-amino-5-nitrobenzonitrile (25.39 g) and sulfuric acid (70 ml) was stirred at 130 C. for 40 min. The reaction mixture was gradually added to ice water, and the precipitate was collected by filtration and washed with water, ethanol and diethyl ether to give 2-amino-5-nitrobenzamide (24.63 g).

References: [1]Archiv der Pharmazie,1994,vol. 327,p. 571 - 579.
[2]Patent: EP1953148,2008,A1 .Location in patent: Page/Page column 130.
[3]Patent: US2015/329556,2015,A1 .Location in patent: Paragraph 1771.
[4]European Journal of Medicinal Chemistry,2018,vol. 143,p. 568 - 576.

7
[ 16313-65-8 ]
[ 108-94-1 ]
6-Nitro-2,3-dihydro-1H-chinazolin-2-spiro-1'-cyclohexan-4-on [ No CAS ]

References: [1]Archiv der Pharmazie,1994,vol. 327,p. 571 - 579.

8
[ 16313-65-8 ]
[ 141-97-9 ]
2-(2-Methyl-6-nitro-4-oxo-1,2,3,4-tetrahydrochinazolin-2-yl)essigsaeureethylester [ No CAS ]

References: [1]Archiv der Pharmazie,1994,vol. 327,p. 571 - 579.

9
[ 16313-65-8 ]
[ 99-61-6 ]
6-nitro-2-(3-nitrophenyl)-1,2-dihydroquinazolin-4(3H)-one [ No CAS ]

References: [1]Archiv der Pharmazie,1994,vol. 327,p. 571 - 579.

10
[ 16313-65-8 ]
[ 123-11-5 ]
6-nitro-2-(4-methoxyphenyl)-1,2-dihydroquinazolin-4(3H)-one [ No CAS ]

References: [1]Archiv der Pharmazie,1994,vol. 327,p. 571 - 579.

11
[ 16313-65-8 ]
[ 120-92-3 ]
6-Nitro-2,3-dihydro-1H-chinazolin-2-spiro-1'-cyclopentan-4-on [ No CAS ]

References: [1]Archiv der Pharmazie,1994,vol. 327,p. 571 - 579.
[2]Synlett,2008,p. 233 - 236.

12
[ 16313-65-8 ]
[ 123-54-6 ]
[ 24688-36-6 ]

References: [1]Archiv der Pharmazie,1994,vol. 327,p. 571 - 579.

13
[ 16313-65-8 ]
[ 20260-53-1 ]
[ 157864-30-7 ]

References: [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 3547 - 3557.

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 2(d) 5-Nitroanthranilamide The product is collected by filtration as a solid. NMR (200 MHz, DMSO-d6): delta 6.80 (dd,1 H), 7.40 (broad, 1H), 7.90 (broad, 2H), 8.03 (dt, 1H), 8.20 (broad, 1H), 8.56 (t, 1H).
		Reference example 2(d) 5-nitroanthranilamide STR23 The product was collected by filtration as a solid. NMR (200 MHz, DMSO-dG): delta 6.80 (dd,l H), 7.40 (broad, 1H), 7.90 (broad, 2H), 8.03 (dt, 1H), 8.20 (broad, 1H), 8.56 (t, 1H).

16
<5-nitro-isatoic acid >-anhydride [ No CAS ]
[ 16313-65-8 ]

References: [1]Journal fur praktische Chemie (Leipzig 1954),1884,vol. <2> 30,p. 474.

17
[ 16313-65-8 ]
[ 149-73-5 ]
[ 6943-17-5 ]

References: [1]Bioorganic and Medicinal Chemistry,2003,vol. 11,p. 383 - 391.
[2]Bioorganic and Medicinal Chemistry Letters,2001,vol. 11,p. 545 - 548.
[3]Bioorganic and Medicinal Chemistry,2003,vol. 11,p. 3869 - 3878.

18
[ 616-79-5 ]
[ 16313-65-8 ]

Yield	Reaction Conditions	Operation in experiment
66%		Example 125 Preparation of 2-(3,5-Dimethoxyphenyl)-6-(pyridin-4-ylamino)quinazolin-4(3H)-one To a mixture of 2-amino-5-nitro-benzoic acid (12.9 g, 81.9 mmol), 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (EDCl) (17.3 g, 90.1 mmol), 1-hydroxybenzotriazole hydrate (HOBt) (12.2 g, 90.1 mmol) in THF (200 mL) was added 4-methylmorpholine (NMM) (9.91 mL, 90.1 mmol). After 10 minutes, ammonium hydroxide (50% v/v, 50 mL) was added. The mixture was stirred at room temperature under nitrogen for 17 hours. Solvent was removed under reduced pressure. Water was added. The solid separated was filtered, washed with aqueous NaHCO3 solution, and with water, and dried in air, to afford 2-amino-5-nitro-benzamide as a yellow solid. Yield: 9.88 g (66%).
65%		Add 9.1g to a dry 100 mL round bottom flask2-amino-5-nitrobenzoic acid,Slowly add 10mL SOCl2,Add 3 drops of DMF as a catalyst,Reflow reaction at 65 C for 3 h,The excess SOCl2 was removed by rotary evaporation.Dissolve 3 mL of ammonia in 16 mL of dichloroethane.Add 5.8g of sodium carbonate,Maintain the temperature 10-15 C,Slowly adding a solution of dichloroethane containing the acid chloride prepared above,After 1 h, the temperature was raised to 25 C for 3 h.Filtering,The filtrate was diluted with dilute hydrochloric acid (2 × 50 mL),10% NaHCO3 (2 x 50 mL),Wash with saturated NaCl (2 x 50 mL) and water (2 x 50 mL).After drying with anhydrous magnesium sulfate,Decompressed product2-amino-5-nitrobenzamide 5.9g,The yield was 65%.

References: [1]Bioorganic and Medicinal Chemistry,2003,vol. 11,p. 383 - 391.
[2]Journal of Medicinal Chemistry,2018,vol. 61,p. 7952 - 7976.
[3]Patent: US9238640,2016,B2 .Location in patent: Page/Page column 154.
[4]Patent: CN109897008,2019,A .Location in patent: Paragraph 0019-0022.
[5]Bioorganic and Medicinal Chemistry,2003,vol. 11,p. 3869 - 3878.
[6]Chinese Chemical Letters,2019,vol. 30,p. 1207 - 1213.
[7]Phosphorus, Sulfur and Silicon and the Related Elements,2020,vol. 195,p. 194 - 200.

19
[ 16313-65-8 ]
[ 19815-16-8 ]

References: [1]Bioorganic and Medicinal Chemistry,2003,vol. 11,p. 3869 - 3878.
[2]Bioorganic and Medicinal Chemistry,2003,vol. 11,p. 383 - 391.
[3]Bioorganic and Medicinal Chemistry Letters,2001,vol. 11,p. 545 - 548.

20
[ 16313-65-8 ]
4-[2-(3-pyridyl)ethylamino]-6-nitroquinazoline [ No CAS ]